Unlocking Novel Peptide Therapies that Overcome Treatment Resistance and Improve Patient Outcomes
What makes us unique
At Aecor.bio, we are addressing one of the greatest challenges across all diseases: Treatment Resistance.
Our patented approach reverses treatment resistance by targeting disrupted gene expression.
We use AI to design protein hydrolysis to generate thousands of bioactive peptide that are assayed for reverse treatment resistance gene expression changes at the cellular level.
Our Focus Areas
-
Target Optimized Peptides: Synthesizing thousands of unique peptides derived from protein hydrolysis using our proprietary algorithms at accelerated speeds and scale.
-
Treatment Resistance: Tackling resistance mechanisms head-on by identifying the gene expression changes that occur during resistance
-
Repairing Cellular Micro-Environments: Resetting gene expression changes that occur during treatment resistance by identifying active peptides that reverse treatment resistance.
Bringing Science, AI-Driven Methodologies and Patient Outcomes
We integrate proprietary peptide design, advanced immunology research, and clinical expertise to develop therapies that go beyond conventional treatments.
Our focus is on creating smarter, targeted solutions that address the root causes of treatment resistance. For cancer patients facing treatment resistance, hope often seems out of reach.
At HBC Immunology, our therapies are designed to overcome these resistance barriers, offering renewed possibilities and better outcomes.